<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138576</url>
  </required_header>
  <id_info>
    <org_study_id>IC4-05682-059-RUS</org_study_id>
    <nct_id>NCT04138576</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Tolerability of Venoactive Drugs in Combination Therapy and Their Effect on the Overall Treatment Outcomes in Patients With Chronic Venous Diseases of CEAP Class C4a and C4b in Real Clinical Practice.</brief_title>
  <acronym>VAP-PRO-C4</acronym>
  <official_title>Evaluation of the Efficacy and Tolerability of Venoactive Drugs in Combination Therapy and Their Effect on the Overall Treatment Outcomes in Patients With Chronic Venous Diseases of CEAP Class C4a and C4b in Real Clinical Practice.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier Russia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at evaluating the efficacy and tolerability of systemic pharmacotherapy as
      a part of combination treatment, and its influence on the overall treatment outcomes in
      patients with skin changes (CEAP class C4a and C4b).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of systemic pharmacotherapy as part of combination therapy: change in the CEAP clinical class of CVD</measure>
    <time_frame>3 month</time_frame>
    <description>- change in the CEAP clinical class of CVD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of systemic pharmacotherapy as part of combination therapy and its impact on the: area of affected skin determined by curvimetry technique (only in selected centers that use this technique routinely): skin density</measure>
    <time_frame>3 month</time_frame>
    <description>before and after the treatment in patients with skin changes of CEAP class C4a or C4b in real clinical practice
- skin density determined by durometry technique (only in selected centers that use this technique routinely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the quality of life (global index score [GIS])</measure>
    <time_frame>3 month</time_frame>
    <description>using the CIVIQ-14 questionnaire ( The resulting instrument comprised 14 items, split into three dimensions (pain, physical, and psychological), and was named CIVIQ-14) (SEE ATTACHMENT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of systemic pharmacotherapy as part of combination therapy in patients with skin changes of CEAP class C4a or C4b: thickness of the skin-fat fold</measure>
    <time_frame>3 month</time_frame>
    <description>thickness of the skin-fat fold (ultrasound examination);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of systemic pharmacotherapy as part of combination therapy in patients with skin changes of CEAP class C4a or C4b: change in the CEAP clinical class of CVD</measure>
    <time_frame>3 month</time_frame>
    <description>change in the CEAP clinical class of CVD. (evolution of CVD symptoms characteristic for CEAP class C4 (sensations of skin tightening, burning, itching, pain, and exudation) using the Visual Analogue Scale (VAS))</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Chronic Venous Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic venous diseases of CEAP class C4a and C4b
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old or above

          -  Written informed consent

          -  Patient did not receive treatment with venoactive drugs within the past 4 -weeks prior
             to the inclusion in the study

          -  Diagnosis of chronic venous disease of CEAP class C4

          -  No surgical intervention for CVD is planned by a doctor

        Exclusion Criteria:

          -  Chronic venous disease of СЕАР class C0-С3 or class С4-С6

          -  History of alcohol or drug abuse or use of narcotic drugs

          -  Peripheral artery disease

          -  Lymphatic edema of the lower extremities

          -  Secondary varicose veins, angiodysplasia, or neoplasia

          -  Arterial disease (ankle-brachial index &lt;0.9)

          -  Infection within the past 6 weeks

          -  Any of the following concomitant diseases, which can affect the results:

          -  Connective tissue disease (including rheumatoid arthritis), arthritis

          -  Heart failure

          -  Chronic kidney disease

          -  Decompensated diabetes mellitus

          -  Skin diseases of non-venous origin

          -  Intermittent claudication (peripheral artery disease)

          -  Diseases of the bones or joints of the lower extremities

          -  Malignancy

        Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal
        drugs, NSAIDs, etc.) History of deep vein thrombosis (within the past year) History of
        superficial thrombophlebitis (within the past 3 months) History of surgical intervention
        (within the past 3 months) Patient cannot walk (regardless of the cause) Predictable poor
        adherence to treatment Participation of a patient in the intervention study within the
        previous 3 months For women: pregnancy or breastfeeding, the desire to become pregnant
        within at least 2 months after the study Patients with a contraindication to
        diosmin-containing agents, including Detralex Patient uses the topical treatments
        contraindicated in case of skin integrity violation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Medical and Surgical Center. N.I. Pirogov</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Stoyko Yuriy, prof</last_name>
      <phone>+7 985 784 88 60</phone>
      <email>ystoyko@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.civiq-20.com/download/CIVIQ-14_English_UK.pdf</url>
    <description>CIVIQ-14 QUASTIONNAIRE</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

